Brentuximab Vedotin

T-Cell Non-Hodgkin Lymphoma

Yale Universityantibody_drug_conjugatePhase 4 / ApprovedActive

BBB

73/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 67/ 100
Competitive Position: 81/ 100

Competitive context

83 Active assets in the T-Cell Non-Hodgkin Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Fludarabine GC Cell Corporation	Phase 2	BBB
Rituximab Memorial Sloan Kettering Cancer Center	Phase 2	BB
LENALIDOMIDE Samsung Medical Center	Phase 2	BB
Cyclophosphamide GC Cell Corporation	Phase 3	BB
TACROLIMUS M.D. Anderson Cancer Center	Phase 2	BB

View all 50 →

Same molecule, other indications

Brentuximab Vedotin is also rated in:

anaplastic large cell lymphomaActive

BBB

Indicative · Phase 3

72 / 100

primary cutaneous T-cell non-Hodgkin lymphomaActive

BB

Indicative · Phase 3

70 / 100

Hodgkins lymphomaActive

BB

Indicative · Phase 4

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.